Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of “Reduce” from Brokerages

Replimune Group, Inc. (NASDAQ:REPL) has been assigned a consensus rating of “Reduce” from the ten research firms that are currently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a sell rating and seven have issued a hold rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $4.8750.

REPL has been the subject of a number of research reports. Cantor Fitzgerald lowered shares of Replimune Group from an “overweight” rating to a “hold” rating in a research report on Monday, April 13th. Leerink Partners reiterated a “market perform” rating and issued a $2.00 price target (down from $11.00) on shares of Replimune Group in a report on Monday, April 13th. Weiss Ratings cut shares of Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, June 3rd. BMO Capital Markets downgraded shares of Replimune Group from a “market perform” rating to an “underperform” rating in a report on Monday, April 13th. Finally, Wall Street Zen upgraded Replimune Group from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 23rd.

Insider Buying and Selling

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the completion of the transaction, the insider owned 180,962 shares in the company, valued at $1,672,088.88. This trade represents a 6.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. International Assets Investment Management LLC bought a new position in Replimune Group during the fourth quarter valued at $29,000. Russell Investments Group Ltd. raised its position in shares of Replimune Group by 3,638.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock valued at $33,000 after buying an additional 7,569 shares in the last quarter. CWM LLC lifted its holdings in shares of Replimune Group by 248.6% in the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock valued at $39,000 after acquiring an additional 2,886 shares during the last quarter. Essential Partners LLC grew its position in Replimune Group by 562,400.0% in the first quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock worth $43,000 after acquiring an additional 5,624 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its position in Replimune Group by 99.8% in the third quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock worth $58,000 after acquiring an additional 6,873 shares in the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Trading Up 3.0%

Shares of REPL opened at $9.24 on Wednesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60. Replimune Group has a 1 year low of $1.50 and a 1 year high of $13.24. The company has a 50 day simple moving average of $5.18 and a two-hundred day simple moving average of $7.27. The firm has a market cap of $762.95 million, a P/E ratio of -2.69 and a beta of 0.91.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.